Sito Bio(SZ:300583)2021-04-19 16:00Financial Performance - The company's revenue for Q1 2021 was CNY 272,376,194.52, representing a 22.60% increase compared to CNY 222,171,115.42 in the same period last year[8] - The net profit attributable to shareholders was a loss of CNY 5,371,348.90, an improvement of 77.84% from a loss of CNY 24,243,112.96 in the previous year[8] - The basic earnings per share were CNY -0.05, improving by 77.27% from CNY -0.22 in the same period last year[8] - The net profit attributable to shareholders was -5.37 million yuan, an increase of 77.84% year-on-year[26] - The net loss for Q1 2021 was CNY 4,955,375.78, a significant improvement from a net loss of CNY 29,031,607.96 in Q1 2020[51] - The company reported a total comprehensive income of CNY 17,798,306.66 for Q1 2021, compared to CNY 5,255,268.42 in Q1 2020, marking an increase of 237.5%[55] Cash Flow - The net cash flow from operating activities was negative at CNY -57,991,155.87, a decline of 843.09% compared to a positive cash flow of CNY 7,804,016.99 in the same period last year[8] - Cash received from operating activities decreased by 843.09%, resulting in a net cash flow of -57.99 million yuan[25] - The total cash flow from operating activities was negative CNY 57,991,155.87, a decline from a positive cash flow of CNY 7,804,016.99 in the same period last year[58] - The net cash flow from operating activities was ¥55,397,320.47, a decrease of 18% compared to ¥67,688,413.19 in the previous period[60] - Total cash inflow from operating activities amounted to ¥151,868,773.20, up 50% from ¥101,222,822.50 in the prior period[60] Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,011,234,104.57, an increase of 5.98% from CNY 2,841,295,244.66 at the end of the previous year[8] - The total current asset of RMB 1.22 billion, up from RMB 1.14 billion, indicating an increase of about 6.9%[41] - The company's total liabilities reached CNY 1,326,112,564.91, compared to CNY 1,149,916,239.64 in the previous year, marking an increase of 15.4%[45] - The company's total liabilities increased to RMB 1.06 billion from RMB 944.00 million, reflecting an increase of about 12.5%[42] Shareholder Information - The company had a total of 12,222 preferred shareholders at the end of the reporting period[12] - The top ten shareholders held a significant portion of the company's shares, with the largest shareholder holding 39,802,720 shares, representing 37.11% of the total[12] - The total equity attributable to shareholders was CNY 1,637,637,435.80, slightly down from CNY 1,643,008,784.70, a decrease of 0.3%[45] Research and Development - R&D expenses increased by 52.60% to ¥11,286,267.83 as a result of accelerated project development[22] - Research and development expenses for Q1 2021 were CNY 11,286,267.83, an increase of 52.5% from CNY 7,395,918.08 in Q1 2020[51] Government Subsidies - The company received government subsidies amounting to CNY 2,811,471.50 during the reporting period[9] - Other income surged by 129.36% to ¥2,811,471.50 due to increased government subsidies related to operating activities[22] Investment Activities - The company invested 112.10 million yuan in fixed assets and intangible assets, a 94.96% increase compared to the previous year[25] - The company raised CNY 130,000,000.00 through financing activities, an increase from CNY 105,000,000.00 in the previous year[59] Operational Efficiency - The company plans to continue expanding its market presence and investing in R&D for new product development[18] - The company has achieved a production efficiency of 56.28% in its raw material drug project as of May 1, 2022[32] Market and Project Updates - The company is advancing the registration and certification of multiple drugs in the US, domestic, and EU markets, with no significant changes in project feasibility[32] - The company is facing increased external uncertainties and trade protectionism, which may impact project timelines and expected returns[32]